Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform

As the American population ages, the healthcare system faces increasing challenges in diagnosing and treating chronic and rare diseases, particularly among older adults. With over 30 million Americans living with a rare disease, the demand for effective treatments is more urgent than ever. Many of these conditions lack FDA-approved therapies, and symptoms in seniors are often mistaken for normal aging, leading to significant delays in diagnosis.

In response to this growing crisis, Soligenix Inc. (NASDAQ: SNGX) has made significant advancements with its HyBryte platform, a novel therapy targeting cutaneous T-cell lymphoma (CTCL), a rare skin cancer predominantly affecting older adults. The successful U.S.-based manufacturing of HyBryte's active ingredient marks a critical step forward in providing much-needed treatment options for this underserved patient population. This development not only underscores the potential of domestic medical innovation but also aligns with broader initiatives to improve access to treatments and accelerate medical advancements in the U.S.

The progress of Soligenix Inc. is part of a larger effort within the pharmaceutical industry to address rare and chronic diseases. Companies like Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), and Bristol-Myers Squibb Co. (NYSE: BMY) are also at the forefront of developing treatments for high-need therapeutic areas. The collective efforts of these companies highlight the industry's commitment to tackling some of the most pressing healthcare challenges facing the aging population.

For more information on Soligenix Inc. and its HyBryte platform, visit https://www.soligenix.com. The advancements in treating rare diseases like CTCL not only offer hope to affected individuals and their families but also demonstrate the critical role of innovation in improving healthcare outcomes for vulnerable populations.